Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report)'s stock price traded up 5.7% on Friday . The company traded as high as $3.60 and last traded at $3.55. 1,281,332 shares traded hands during mid-day trading, a decline of 8% from the average session volume of 1,395,790 shares. The stock had previously closed at $3.36.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on the stock. HC Wainwright raised their price objective on shares of Xeris Biopharma from $6.00 to $6.60 and gave the stock a "buy" rating in a report on Monday, November 11th. Piper Sandler lowered shares of Xeris Biopharma from an "overweight" rating to a "neutral" rating and set a $3.00 price target for the company. in a research note on Monday, November 11th.
View Our Latest Research Report on Xeris Biopharma
Xeris Biopharma Stock Performance
The firm has a market capitalization of $506.88 million, a P/E ratio of -7.56 and a beta of 2.62. The stock has a 50 day moving average of $3.34 and a 200-day moving average of $2.90.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of XERS. Walleye Capital LLC bought a new position in shares of Xeris Biopharma in the third quarter worth $3,197,000. Renaissance Technologies LLC grew its holdings in Xeris Biopharma by 33.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company's stock valued at $3,041,000 after buying an additional 342,300 shares in the last quarter. Barclays PLC increased its position in shares of Xeris Biopharma by 87.8% during the third quarter. Barclays PLC now owns 324,472 shares of the company's stock valued at $925,000 after buying an additional 151,685 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Xeris Biopharma by 2.9% in the third quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company's stock worth $9,502,000 after buying an additional 93,091 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Xeris Biopharma during the third quarter valued at approximately $237,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Further Reading
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
